Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus TAS-102 in RAS wild-type unresectable advanced/recurrent colorectal cancer
jRCT1080223022Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, trifluridine and tipiracil in colorectal adenocarcinoma, sponsored by Takeda. Started Nov 2015; status: completed.
02
Drugs
panitumumabtrifluridinetipiracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT1080223022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223022.